Testimonials

Background stories of how others approached and experienced their European Horizon funding trajectory.

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Published on | 7 months ago

Programmes Health

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.

Read the full article for details 
Other available testimonials

Testimonial

image of Avia-GIS - Software Technologies for a Healthier World

Avia-GIS - Software Technologies for a Healthier World

Avia-GIS is a Belgian innovative SME established in 2001. They have built research and public authority trust over the past 19 years and developed a unique, disruptive software suite - VECMAP® - that supports society to overcome one of its important health threats, the spreading of Pests of Public Health importance.

With the help of a Horizon 2020 SME Instrument Phase 2 project, they will be able to add Integrated Pest Management functionalities and go to the market. With the grant, that was an essential component of their second investment round, Avia-GIS aims at raising its revenue from the current 2 M€ to 14.2 M€ in 2024, and increase the headcount from 15 to 58.